MAPT and Alzheimer disease: Careful delineation of the neuroprotective mechanisms of rapamycin in the perforant pathway, and additional insights into neuron-specific signaling mechanisms regulating the degradation of aggregation-prone pathological proteins should foster the development of novel therapeutic strategies for impeding the tau-mediated pathology and progressive brain atrophy in AD.